Biogen Soars 46% on Alzheimer’s Drug Trial. Mizuho Says the Inventory Is a Purchase.

Biogen


shares were soaring Wednesday after the biopharmaceutical company said that its experimental Alzheimer’s drug with Japan-based partner 


Eisai

Guggenheim Securities analyst Yatin Suneja called the data “a new dawn for Alzheimer’s treatment.”